Skip to main content
Top
Published in: Medical Oncology 4/2020

01-04-2020 | Nephrectomy | Original Paper

Percutaneous microwave ablation therapy of renal cancer local relapse after radical nephrectomy: a feasibility and efficacy study

Authors: Anna Maria Ierardi, Aldo Carnevale, Umberto G. Rossi, Matteo Renzulli, Enrico Garanzini, Rita Golfieri, Nicola Macchione, Corrado Cittanti, Melchiore Giganti, Gianpaolo Carrafiello

Published in: Medical Oncology | Issue 4/2020

Login to get access

Abstract

Renal cell carcinoma (RCC) local recurrence after radical nephrectomy is uncommon. When feasible, surgical removal remains the primary treatment strategy; nevertheless, local RCC relapse management is controversial, and less invasive procedures may represent an attractive option to achieve oncologic control. The aim of our study was to assess the feasibility, safety, and clinical outcomes of image-guided percutaneous microwave ablation (MWA) for RCC local recurrence in patients initially treated with nephrectomy with curative intent. 10 consecutive patients underwent CT-guided percutaneous MWA of a total of 10 retroperitoneal nodules. Inclusion criteria were: histologically verified retroperitoneal metastases, previous radical nephrectomy, lesion no larger than 3 cm, no other metastatic site elsewhere. All the procedures were performed under moderate sedation choosing the most favorable patient decubitus. If deemed necessary, pneumodissection was induced before ablation. After the antenna placement inside the target lesion, thermal ablation was achieved by maintenance of a power of 100 W for a total time between 2 and 4 min. All patients were observed overnight and discharged the following day if clinically stable. Technical success was obtained in 100% of patients. One patient was re-treated to complete oncologic response with repeat MWA. No major complications were observed. No patients demonstrated local recurrence at a mean follow-up of 26 months. MWA is a safe and effective treatment strategy for loco-regional relapse of RCC following radical nephrectomy. This technique may represent a valuable approach for patients who are not eligible for surgery.
Literature
2.
go back to reference Krokidis ME, Orsi F, Katsanos K, Helmberger T, Adam A. CIRSE Guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Intervent Radiol. 2017;40:177–91.CrossRef Krokidis ME, Orsi F, Katsanos K, Helmberger T, Adam A. CIRSE Guidelines on percutaneous ablation of small renal cell carcinoma. Cardiovasc Intervent Radiol. 2017;40:177–91.CrossRef
3.
go back to reference Bartoletti R, Cai T, Tosoratti N, Amabile C, Crisci A, Tinacci G, et al. In vivo microwave-induced porcine kidney thermoablation: results and perspectives from a pilot study of a new probe. BJU Int. 2010;106:1817–21.CrossRef Bartoletti R, Cai T, Tosoratti N, Amabile C, Crisci A, Tinacci G, et al. In vivo microwave-induced porcine kidney thermoablation: results and perspectives from a pilot study of a new probe. BJU Int. 2010;106:1817–21.CrossRef
4.
go back to reference Chan P, Vélasco S, Vesselle G, Boucebci S, Herpe G, Debaene B, et al. Percutaneous microwave ablation of renal cancers under CT guidance: safety and efficacy with a 2-year follow-up. Clin Radiol Elsevier. 2017;72:786–92.CrossRef Chan P, Vélasco S, Vesselle G, Boucebci S, Herpe G, Debaene B, et al. Percutaneous microwave ablation of renal cancers under CT guidance: safety and efficacy with a 2-year follow-up. Clin Radiol Elsevier. 2017;72:786–92.CrossRef
5.
go back to reference Carrafiello G, Laganà D, Mangini M, Fontana F, Dionigi G, Boni L, et al. Microwave tumors ablation: principles, clinical applications and review of preliminary experiences. Int J Surg. 2008;6:S65–S6969.CrossRef Carrafiello G, Laganà D, Mangini M, Fontana F, Dionigi G, Boni L, et al. Microwave tumors ablation: principles, clinical applications and review of preliminary experiences. Int J Surg. 2008;6:S65–S6969.CrossRef
6.
go back to reference Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000;164:322–5.CrossRef Itano NB, Blute ML, Spotts B, Zincke H. Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol. 2000;164:322–5.CrossRef
7.
go back to reference Acar Ö, Şanlı Ö. Surgical management of local recurrences of renal cell carcinoma. Surg Res Pract. 2016;2016:1–6.CrossRef Acar Ö, Şanlı Ö. Surgical management of local recurrences of renal cell carcinoma. Surg Res Pract. 2016;2016:1–6.CrossRef
8.
go back to reference Zhou W, Herwald SE, Uppot RN, Arellano RS. Image-guided thermal ablation for non-resectable recurrence of renal cell cancer following nephrectomy: clinical experience with eleven patients. Cardiovasc Intervent Radiol. 2018;41:1743–50.CrossRef Zhou W, Herwald SE, Uppot RN, Arellano RS. Image-guided thermal ablation for non-resectable recurrence of renal cell cancer following nephrectomy: clinical experience with eleven patients. Cardiovasc Intervent Radiol. 2018;41:1743–50.CrossRef
9.
go back to reference Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2009;20:S240–S249249.CrossRef Malloy PC, Grassi CJ, Kundu S, Gervais DA, Miller DL, Osnis RB, et al. Consensus guidelines for periprocedural management of coagulation status and hemostasis risk in percutaneous image-guided interventions. J Vasc Interv Radiol. 2009;20:S240–S249249.CrossRef
10.
go back to reference Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRef
11.
go back to reference Cardella JF, Kundu S, Miller DL, Millward SF, Sacks D. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2009;20:S189–S191191.CrossRef Cardella JF, Kundu S, Miller DL, Millward SF, Sacks D. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2009;20:S189–S191191.CrossRef
12.
go back to reference Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40:1141–6.CrossRef Filippiadis DK, Binkert C, Pellerin O, Hoffmann RT, Krajina A, Pereira PL. Cirse quality assurance document and standards for classification of complications: the cirse classification system. Cardiovasc Intervent Radiol. 2017;40:1141–6.CrossRef
13.
go back to reference Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R, et al. Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urol Oncol Semin Orig Investig. 2018;36:11.e1–.e6.CrossRef Herout R, Graff J, Borkowetz A, Zastrow S, Leike S, Koch R, et al. Surgical resection of locally recurrent renal cell carcinoma after nephrectomy: Oncological outcome and predictors of survival. Urol Oncol Semin Orig Investig. 2018;36:11.e1–.e6.CrossRef
14.
go back to reference Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;25:49–56.CrossRef Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;25:49–56.CrossRef
15.
go back to reference McLaughlin CA, Chen MY, Torti FM, Hall MC, Zagoria RJ. Radiofrequency ablation of isolated local recurrence of renal cell carcinoma after radical nephrectomy. Am J Roentgenol. 2003;181:93–4.CrossRef McLaughlin CA, Chen MY, Torti FM, Hall MC, Zagoria RJ. Radiofrequency ablation of isolated local recurrence of renal cell carcinoma after radical nephrectomy. Am J Roentgenol. 2003;181:93–4.CrossRef
16.
go back to reference Bang HJ, Littrup PJ, Goodrich DJ, Currier BP, Aoun HD, Heilbrun LK, et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol. 2012;23:770–7.CrossRef Bang HJ, Littrup PJ, Goodrich DJ, Currier BP, Aoun HD, Heilbrun LK, et al. Percutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation. J Vasc Interv Radiol. 2012;23:770–7.CrossRef
17.
go back to reference Monfardini L, Varano GM, Foà R, Della Vigna P, Bonomo G, Orsi F. Local recurrence of renal cancer after surgery: prime time for percutaneous thermal ablation? Cardiovasc Intervent Radiol. 2015;38:1542–7.CrossRef Monfardini L, Varano GM, Foà R, Della Vigna P, Bonomo G, Orsi F. Local recurrence of renal cancer after surgery: prime time for percutaneous thermal ablation? Cardiovasc Intervent Radiol. 2015;38:1542–7.CrossRef
Metadata
Title
Percutaneous microwave ablation therapy of renal cancer local relapse after radical nephrectomy: a feasibility and efficacy study
Authors
Anna Maria Ierardi
Aldo Carnevale
Umberto G. Rossi
Matteo Renzulli
Enrico Garanzini
Rita Golfieri
Nicola Macchione
Corrado Cittanti
Melchiore Giganti
Gianpaolo Carrafiello
Publication date
01-04-2020
Publisher
Springer US
Published in
Medical Oncology / Issue 4/2020
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-020-01354-0

Other articles of this Issue 4/2020

Medical Oncology 4/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.